|
1
|
Torre LA, Siegel RL and Jemal A: Lung
Cancer Statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and
Bray F: Cancer incidence and mortality patterns in Europe:
Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tsao AS, Scagliotti GV, Bunn PA Jr,
Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU,
McWilliams A, Tsao MS, et al: Scientific advances in lung cancer
2015. J Thorac Oncol. 11:613–638. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gagan J and Van Allen EM: Next-generation
sequencing to guide cancer therapy. Genome Med. 7:802015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Diaz Z, Aguilar-Mahecha A, Paquet ER,
Basik M, Orain M, Camlioglu E, Constantin A, Benlimame N, Bachvarov
D, Jannot G, et al: Next-generation biobanking of metastases to
enable multidimensional molecular profiling in personalized
medicine. Mod Pathol. 26:1413–1424. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Meldrum C, Doyle MA and Tothill RW:
Next-generation sequencing for cancer diagnostics: A practical
perspective. Clin Biochem Rev. 32:177–195. 2011.PubMed/NCBI
|
|
7
|
Pavlopoulou A, Spandidos DA and
Michalopoulos I: Human cancer databases (Review). Oncol Rep.
33:3–18. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Forbes SA, Beare D, Gunasekaran P, Leung
K, Bindal N, Boutselakis H, Ding M, Bamford S, Cole C, Ward S, et
al: COSMIC: Exploring the world's knowledge of somatic mutations in
human cancer. Nucleic Acids Res. 43:D805–D811. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chin L, Hahn WC, Getz G and Meyerson M:
Making sense of cancer genomic data. Genes Dev. 25:534–555. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu TJ, Schriml LM, Chen QR, Colbert M,
Crichton DJ, Finney R, Hu Y, Kibbe WA, Kincaid H, Meerzaman D, et
al: Generating a focused view of disease ontology cancer terms for
pan-cancer data integration and analysis. Database (Oxford).
2015:bav0322015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dumur CI: Available resources and
challenges for the clinical annotation of somatic variations.
Cancer Cytopathol. 122:730–736. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu L, Li Y, Li S, Hu N, He Y, Pong R, Lin
D, Lu L and Law M: Comparison of next-generation sequencing
systems. J Biomed Biotechnol. 2012:2513642012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tops BB, Normanno N, Kurth H, Amato E,
Mafficini A, Rieber N, Le Corre D, Rachiglio AM, Reiman A, Sheils
O, et al: Development of a semi-conductor sequencing-based panel
for genotyping of colon and lung cancer by the Onconetwork
consortium. BMC Cancer. 15:262015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
D'Haene N, Le Mercier M, De Nève N,
Blanchard O, Delaunoy M, El Housni H, Dessars B, Heimann P,
Remmelink M, Demetter P, et al: Clinical validation of targeted
next generation sequencing for colon and lung cancers. PLoS One.
10:e01382452015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jennings LJ, Arcila ME, Corless C,
Kamel-Reid S, Lubin IM, Pfeifer J, Temple-Smolkin RL, Voelkerding
KV and Nikiforova MN: Guidelines for validation of next-generation
sequencing-based oncology panels: A joint consensus recommendation
of the Association for Molecular Pathology and College of American
Pathologists. J Mol Diagn. 19:341–365. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shahsiah R, DeKoning J, Samie S,
Latifzadeh SZ and Kashi ZM: Validation of a next generation
sequencing panel for detection of hotspot cancer mutations in a
clinical laboratory. Pathol Res Pract. 213:98–105. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Travis WD, Brambilla E, Nicholson AG,
Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E,
Flieder DB, et al: WHO Panel: The 2015 World Health Organization
Classification of Lung Tumors: Impact of Genetic, Clinical and
Radiologic Advances Since the 2004 Classification. J Thorac Oncol.
10:1243–1260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Papadopoulou E, Tsoulos N, Tsirigoti A,
Apessos A, Agiannitopoulos K, Metaxa-Mariatou V, Zarogoulidis K,
Zarogoulidis P, Kasarakis D, Kakolyris S, et al: Determination of
EGFR and KRAS mutational status in Greek non-small-cell lung cancer
patients. Oncol Lett. 10:2176–2184. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Negru S, Papadopoulou E, Apessos A,
Stanculeanu DL, Ciuleanu E, Volovat C, Croitoru A, Kakolyris S,
Aravantinos G, Ziras N, et al: KRAS, NRAS and BRAF mutations in
Greek and Romanian patients with colorectal cancer: A cohort study.
BMJ Open. 4:e0046522014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Scoccianti C, Vesin A, Martel G, Olivier
M, Brambilla E, Timsit JF, Tavecchio L, Brambilla C, Field JK and
Hainaut P: European Early Lung Cancer Consortium: Prognostic value
of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: The
EUELC cohort. Eur Respir J. 40:177–184. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tam IY, Leung EL, Tin VP, Chua DT, Sihoe
AD, Cheng LC, Chung LP and Wong MP: Double EGFR mutants containing
rare EGFR mutant types show reduced in vitro response to gefitinib
compared with common activating missense mutations. Mol Cancer
Ther. 8:2142–2151. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Costa DB: Kinase inhibitor-responsive
genotypes in EGFR mutated lung adenocarcinomas: Moving past common
point mutations or indels into uncommon kinase domain duplications
and rearrangements. Transl Lung Cancer Res. 5:331–337. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kempf E, Rousseau B, Besse B and Paz-Ares
L: KRAS oncogene in lung cancer: Focus on molecularly driven
clinical trials. Eur Respir Rev. 25:71–76. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ahrendt SA, Decker PA, Alawi EA, Zhu Yr
YR, Sanchez-Cespedes M, Yang SC, Haasler GB, Kajdacsy-Balla A,
Demeure MJ and Sidransky D: Cigarette smoking is strongly
associated with mutation of the K-ras gene in patients with primary
adenocarcinoma of the lung. Cancer. 92:1525–1530. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cardarella S, Ogino A, Nishino M, Butaney
M, Shen J, Lydon C, Yeap BY, Sholl LM, Johnson BE and Jänne PA:
Clinical, pathologic, and biologic features associated with BRAF
mutations in non-small cell lung cancer. Clin Cancer Res.
19:4532–4540. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Villaruz LC, Socinski MA, Abberbock S,
Berry LD, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Varella-Garcia M,
Franklin WA, Camidge DR, et al: Clinicopathologic features and
outcomes of patients with lung adenocarcinomas harboring BRAF
mutations in the Lung Cancer Mutation Consortium. Cancer.
121:448–456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nguyen-Ngoc T, Bouchaab H, Adjei AA and
Peters S: BRAF alterations as therapeutic targets in non-small-cell
lung cancer. J Thorac Oncol. 10:1396–1403. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dutt A, Ramos AH, Hammerman PS, Mermel C,
Cho J, Sharifnia T, Chande A, Tanaka KE, Stransky N, Greulich H, et
al: Inhibitor-sensitive FGFR1 amplification in human non-small cell
lung cancer. PLoS One. 6:e203512011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jorge SE, Schulman S, Freed JA, VanderLaan
PA, Rangachari D, Kobayashi SS, Huberman MS and Costa DB: Responses
to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and
co-occurring mutations in lung adenocarcinomas with MET
amplification or MET exon 14 skipping mutation. Lung Cancer.
90:369–374. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mar N, Vredenburgh JJ and Wasser JS:
Targeting HER2 in the treatment of non-small cell lung cancer. Lung
Cancer. 87:220–225. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Collisson EA, Campbell JD, Brooks AN,
Berger AH, Lee W, Chmielecki J, Beer DG, Cope L, Creighton CJ,
Danilova L, et al: Cancer Genome Atlas Research Network:
Comprehensive molecular profiling of lung adenocarcinoma. Nature.
511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hirsch FR, Suda K, Wiens J and Bunn PA Jr:
New and emerging targeted treatments in advanced non-small-cell
lung cancer. Lancet. 388:1012–1024. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kamps R, Brandão RD, Bosch BJ, Paulussen
AD, Xanthoulea S, Blok MJ and Romano A: Next-generation sequencing
in oncology: Genetic diagnosis, risk prediction and cancer
classification. Int J Mol Sci. 18:E3082017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Takeda M, Sakai K, Terashima M, Kaneda H,
Hayashi H, Tanaka K, Okamoto K, Takahama T, Yoshida T, Iwasa T, et
al: Clinical application of amplicon-based next-generation
sequencing to therapeutic decision making in lung cancer. Ann
Oncol. 26:2477–2482. 2015.PubMed/NCBI
|
|
35
|
de Leng WW, Gadellaa-van Hooijdonk CG,
Barendregt-Smouter FA, Koudijs MJ, Nijman I, Hinrichs JW, Cuppen E,
van Lieshout S, Loberg RD, de Jonge M, et al: Targeted next
generation sequencing as a reliable diagnostic assay for the
detection of somatic mutations in tumours using minimal DNA amounts
from formalin fixed paraffin embedded material. PLoS One.
11:e01494052016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Siu LL, Conley BA, Boerner S and LoRusso
PM: Next-generation sequencing to guide clinical trials. Clin
Cancer Res. 21:4536–4544. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rashdan S and Gerber DE: Going into
BATTLE: Umbrella and basket clinical trials to accelerate the study
of biomarker-based therapies. Ann Transl Med. 4:5292016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sundar R, Chénard-Poirier M, Collins DC
and Yap TA: Imprecision in the era of precision medicine in
non-small cell lung cancer. Front Med (Lausanne).
4:392017.PubMed/NCBI
|
|
39
|
Colwell J: NCI-MATCH trial draws strong
interest. Cancer Discov. 6:3342016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Markman M: Maurie Markman on the
Groundbreaking TAPUR Trial. Oncology (Williston Park). 31:158–168.
2017.PubMed/NCBI
|
|
41
|
Herbst RS, Gandara DR, Hirsch FR, Redman
MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS,
Bradley JD, et al: Lung master protocol (Lung-MAP)-A
biomarker-driven protocol for accelerating development of therapies
for squamous cell lung cancer: SWOG S1400. Clin Cancer Res.
21:1514–1524. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Middleton G, Crack LR, Popat S, Swanton C,
Hollingsworth SJ, Buller R, Walker I, Carr TH, Wherton D and
Billingham LJ: The National Lung Matrix Trial: Translating the
biology of stratification in advanced non-small-cell lung cancer.
Ann Oncol. 26:2464–2469. 2015.PubMed/NCBI
|
|
43
|
Kim C and Giaccone G: Lessons learned from
BATTLE-2 in the war on cancer: The use of Bayesian method in
clinical trial design. Ann Transl Med. 4:4662016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chan BA and Hughes BG: Targeted therapy
for non-small cell lung cancer: Current standards and the promise
of the future. Transl Lung Cancer Res. 4:36–54. 2015.PubMed/NCBI
|
|
45
|
Rothschild SI: Targeted therapies in
non-small cell lung cancer-beyond EGFR and ALK. Cancers (Basel).
7:930–949. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zer A and Leighl N: Promising targets and
current clinical trials in metastatic non-squamous NSCLC. Front
Oncol. 4:3292014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kohno T, Nakaoku T, Tsuta K, Tsuchihara K,
Matsumoto S, Yoh K and Goto K: Beyond ALK-RET, ROS1 and other
oncogene fusions in lung cancer. Transl Lung Cancer Res. 4:156–164.
2015.PubMed/NCBI
|
